Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)

Phase 3

Completed

• Conditions: Prevention of Ebola Infection
• Interventions: Biological: V920 Consistency Lot B; Biological: V920 Consistency Lot A; Biological: V920 High-dose Lot; Biological: V920 Consistency Lot C; Biological: Placebo to V920

• Registration Number: NCT02503202
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The study evaluated the safety and immunogenicity of 3 consistency lots and a high-dose lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in healthy adults. The primary purpose of this study was to demonstrate consistency in the immune responses of participants receiving 3 separate lots of V920 through 28 days postvaccination. In addition to the 3 lot groups, a high-dose group and a placebo group were studied. A subset of participants representative of all treatment groups continued through 24 months postvaccination in the extension study for the evaluation of long-term safety. The primary hypothesis states that the geometric mean titer of anti-Zaire ebolavirus envelope (ZEBOV) glycoprotein antibody at 28 days postvaccination is equivalent across the three consistency lots.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-07-17
• Study First Submitted QC: 2015-07-17
• Study First Posted: 2015-07-20
• Study Start: 2015-08-17
• Primary Completion: 2016-05-02
• Study Completion: 2017-09-29
• Results First Submitted: 2018-09-07
• Status Verified: 2018-10
• Results First Submitted QC: 2018-10-09
• Last Update Submitted: 2018-10-09
• Results First Posted: 2018-10-12
• Last Update Posted: 2018-10-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1197

Inclusion Criteria

• Not of reproductive potential, or of reproductive potential and agrees to avoid becoming pregnant or impregnating a partner for 2 months following study vaccination.

Exclusion Criteria

• Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 90 days of participation in this trial.
• Has previously been randomized in another clinical trial and received V920 or any other Ebola vaccine.
• Has been exposed to Ebola virus at any time prior to study entry.
• Is pregnant or breastfeeding or plans to conceive within 2 months following study vaccination.
• Has direct household exposure to a pregnant or lactating woman at the time of participation in this trial.
• Has had a fever (≥100.5ºF/38.0ºC) within 48 hours prior to study entry.
• Has received systemic corticosteroids (equivalent of ≥2 mg/kg total daily dose of prednisone or ≥20 mg/day for persons weighing >10 kg) for ≥14 consecutive days and has not completed treatment at least 30 days prior to study entry.
• Has received systemic corticosteroids exceeding physiologic replacement doses (~5 mg/day prednisone equivalent) within 14 days prior to study entry.
• Has received any live virus vaccine within 30 days prior to study entry or any other (nonlive virus) vaccine within 14 days prior to study entry.
• Has known or suspected impairment of immunological function (e.g., HIV positive).
• Has direct household exposure to a person with known or suspected impairment of immunological function (e.g., HIV positive).
• Has a clinically significant history of intravenous (IV) drug abuse within 12 months prior to study entry.
• Has a known allergy/sensitivity or contraindication to investigational product(s) or its/their excipients (e.g., albumin).
• Has a history of malignancy <=5 years prior to study entry except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
• Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
V920 Consistency Lot B	V920 Consistency Lot B	Participants received a 1.0 mL intramuscular injection of V920 on Day 1
V920 Consistency Lot A	V920 Consistency Lot A	Participants received a 1.0 mL intramuscular injection of V920 on Day 1
V920 High-dose Lot	V920 High-dose Lot	Participants received a 1.0 mL intramuscular injection of V920 on Day 1
V920 Consistency Lot C	V920 Consistency Lot C	Participants received a 1.0 mL intramuscular injection of V920 on Day 1
Placebo to V920	Placebo to V920	Participants received a 1.0 mL intramuscular injection of placebo on Day 1

Primary Outcome Measures

Name	Time	Method
Geometric Mean Titer of Anti-ZEBOV Glycoprotein Antibody	Day 28 postvaccination	Serum was collected for determination of geometric mean titer (GMT) of anti-Zaire ebolavirus envelope (ZEBOV) glycoprotein antibodies using an enzyme-linked immunosorbent assay (GP-ELISA). The unit of measure is ELISA units/mL (EU/mL). The lower limit of quantification for the assay was 36.11 EU/mL.
Percentage of Participants With Elevated Maximum Temperature	Up to Day 42 postvaccination	Participants were instructed on the VRC to take and record their oral (or oral equivalent) temperature daily from the day of vaccination through Day 42. Elevated temperature was defined as ≥38.0° C (≥100.4° F).
Percentage of Participants With Rash Adverse Events Prompted on the Vaccination Report Card	Up to Day 42 postvaccination	An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Rash AEs prompted on the VRC were petechial rash, purpuric rash, and vesicular-type rash.
Percentage of Participants With Vesicular Lesion Adverse Events Prompted on the Vaccination Report Card	Up to Day 42 postvaccination	An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Vesicular lesion AEs prompted on the VRC included blister and rash vesicular.
Percentage of Participants Reporting Serious Adverse Events	Up to Month 6 postvaccination	An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. A serious AE (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is any other important medical event, is a cancer, or is associated with an overdose.
Percentage of Participants With Arthralgia or Arthritis Adverse Events Prompted on the Vaccination Report Card	From Day 5 to Day 42 postvaccination	An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Adverse events of arthralgia and arthritis were prompted on the VRC.
Percentage of Participants With Injection-site Adverse Events Prompted on the Vaccination Report Card	Up to Day 5 postvaccination	An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling.